Related Experiment Video
Updated: Feb 12, 2026
Monitoring Dendritic Cell Migration using 19F / 1H Magnetic Resonance Imaging
Published on: March 20, 2013
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
Maarten Versteven1, Johan M J Van den Bergh1, Elly Marcq2
1Laboratory of Experimental Hematology, Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.
Abstract:
Two decades of clinical cancer research with dendritic cell (DC)-based vaccination have proved that this type of personalized medicine is safe and has the capacity to improve survival, but monotherapy is unlikely to cure the cancer. Designed to empower the patient's antitumor immunity, huge research efforts are set to improve the efficacy of next-generation DC vaccines and to find synergistic combinations with existing cancer therapies. Immune checkpoint approaches, aiming to breach immune suppression and evasion to reinforce antitumor immunity, have been a revelation in the immunotherapy field. Early success of therapeutic antibodies blocking the programmed death-1 (PD-1) pathway has sparked the development of novel inhibitors and combination therapies. Hence, merging immunoregulatory tumor-specific DC strategies with PD-1-targeted approaches is a promising path to explore. In this review, we focus on the role of PD-1-signaling in DC-mediated antitumor immunity. In the quest of exploiting the full potential of DC therapy, different strategies to leverage DC immunopotency by impeding PD-1-mediated immune regulation are discussed, including the most advanced research on targeted therapeutic antibodies, lessons learned from chemotherapy-induced immune activation, and more recent developments with soluble molecules and gene-silencing techniques. An overview of DC/PD-1 immunotherapy combinations that are currently under preclinical and clinical investigation substantiates the clinical potential of such combination strategies.
Insights
Dendritic cell (DC) vaccines show promise in cancer treatment but require combination therapies. Combining DC vaccines with PD-1 blockade strategies enhances antitumor immunity and survival, offering a promising path for cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Dendritic cell (DC) vaccination is a safe personalized cancer therapy improving survival but not curative as monotherapy.
- Immune checkpoint inhibitors, particularly targeting the programmed death-1 (PD-1) pathway, have revolutionized cancer immunotherapy.
- Combining DC-based strategies with PD-1 blockade offers a promising approach to enhance antitumor immunity.
Purpose of the Study:
- To review the role of PD-1 signaling in DC-mediated antitumor immunity.
- To explore strategies for enhancing DC vaccine efficacy by modulating PD-1 immune regulation.
- To discuss the potential of combining DC therapies with PD-1 targeted approaches.
Main Methods:
- Review of preclinical and clinical research on DC/PD-1 immunotherapy combinations.
- Discussion of strategies to leverage DC immunopotency by impeding PD-1-mediated immune regulation.
- Analysis of therapeutic antibodies, chemotherapy-induced immune activation, soluble molecules, and gene-silencing techniques.
Main Results:
- DC-based vaccination is safe and improves survival but is not a standalone cure.
- PD-1 pathway blockade has shown significant success in cancer immunotherapy.
- Various strategies exist to enhance DC immunopotency by targeting PD-1 signaling.
Conclusions:
- Combining dendritic cell vaccines with PD-1 targeted therapies is a promising strategy for cancer treatment.
- Further research and clinical investigations into DC/PD-1 immunotherapy combinations are warranted.
- Modulating PD-1 signaling can significantly enhance the efficacy of DC-based cancer vaccines.
Related Concept Videos
01:29Neuromuscular Junction And Blockade
01:18Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
01:16Structural Joints: Synovial Joints
01:03Structural Joints: Fibrous Joints
Suture
All the bones of the skull, except for the mandible, are joined to each other by a fibrous joint called a suture. The fibrous connective tissue found at a suture strongly unites the adjacent skull bones and thus helps to protect the brain and form the face. In...
01:17Structural Joints: Cartilaginous Joints
There are two types of cartilaginous joints:
Synchondrosis
A synchondrosis ("joined by cartilage") is a cartilaginous joint where bones are connected by hyaline cartilage. Synchondrosis may be temporary...